Taken together, the data suggest that AXL upregulation activates AKT, ERK, or NF-κB signaling to promote resistance to docetaxel treatment in prostate cancer, perhaps in association with the acquisition of EMT. Here, NFKB1 is linked to prostate carcinoma.